Ulodesine clinical trials
Also written BCX4208.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses ulodesine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ulodesine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal InsufficiencyCompletedPhase 2BioCryst PharmaceuticalsNCT01407874Written as Ulodesine (BCX4208) 5 mg
- Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to AllopurinolCompletedPhase 2BioCryst PharmaceuticalsNCT01265264Written as ulodesine
- Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With GoutCompletedPhase 2BioCryst PharmaceuticalsNCT00985127Written as BCX4208
- Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/GoutCompletedPhase 2BioCryst PharmaceuticalsNCT01129648Written as BCX4208
Codes
What other systems call ulodesine · ClinicalTrials.gg INT000129
- MeSH (NLM) C000593472ulodesineOne source NLM
- UNII (FDA) JNG8L9460YULODESINEConfirmed FDA, NLM, Wikidata
- Wikidata Q27281592ulodesineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152793UlodesineOne source FDA
- DrugBank DB12353One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000593472 | ulodesine | One source NLM |
| UNII (FDA) | JNG8L9460Y | ULODESINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27281592 | ulodesine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152793 | Ulodesine | One source FDA |
| DrugBank | DB12353 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.